All Stories

  1. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer

    Article • Nature Genetics, February 2023, Springer Science + Business Media

    Dr Elizabeth L Christie

  2. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

    Article • Nature Genetics, December 2022, Springer Science + Business Media

    Dr Elizabeth L Christie

  3. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members

    Article • Journal of Clinical Oncology, June 2022, American Society of Clinical Oncology (ASCO)

    Dr Elizabeth L Christie

  4. Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

    Article • Cancers, November 2021, MDPI AG

    Dr Elizabeth L Christie

  5. Tumor-derived MMPs regulate cachexia in a Drosophila cancer model

    Article • Developmental Cell, September 2021, Elsevier

    Dr Elizabeth L Christie

  6. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer

    Article • Nature Communications, May 2021, Springer Science + Business Media

    Dr Elizabeth L Christie

  7. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

    Article • Cell, April 2021, Elsevier

    Dr Elizabeth L Christie

  8. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

    Article • January 2021, OAE Publishing

    Dr Elizabeth L Christie

  9. The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer

    Article • January 2021, Elsevier

    Dr Elizabeth L Christie

  10. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

    Article • Nature Communications, November 2020, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  11. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer

    Article • Cancer Research, November 2020, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  12. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

    Article • Blood Advances, October 2020, American Society of Hematology

    Dr Elizabeth L Christie

  13. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

    Article • Nature Communications, September 2020, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  14. Sex differences in oncogenic mutational processes

    Article • Nature Communications, August 2020, Springer Science + Business Media

    Taobo Hu, Dr Elizabeth L Christie

  15. Inferring structural variant cancer cell fraction

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  16. Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  17. Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis

    Article • Communications Biology, February 2020, Springer Science + Business Media

    Andrés Lanzós, Dr Elizabeth L Christie, Taobo Hu

  18. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  19. Combined burden and functional impact tests for cancer driver discovery using DriverPower

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  20. Divergent mutational processes distinguish hypoxic and normoxic tumours

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  21. Genomic footprints of activated telomere maintenance mechanisms in cancer

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  22. High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  23. Integrative pathway enrichment analysis of multivariate omics data

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  24. Pathway and network analysis of more than 2500 whole cancer genomes

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  25. Pan-cancer analysis of whole genomes

    Article • Nature, February 2020, Springer Science + Business Media

    Taobo Hu, Anna Ehinger, Professor Daniel S. Brewer, Dr Elizabeth L Christie

  26. The evolutionary history of 2,658 cancers

    Article • Nature, February 2020, Springer Science + Business Media

    Dr Elizabeth L Christie, Taobo Hu

  27. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer

    Article • Molecular Cancer Research, August 2019, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  28. TARGETING MULTIDRUG RESISTANCE PROTEIN 1 (MDR1) POTENTIATES SMAC-MIMETIC THERAPY TO KILL LEUKEMIC STEM CELLS AND OVERCOME RESISTANCE IN ACUTE MYELOID LEUKEMIA

    Article • Experimental Hematology, August 2019, Elsevier

    Dr Elizabeth L Christie

  29. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer

    Article • Nature Communications, March 2019, Springer Science + Business Media

    Dr Elizabeth L Christie

  30. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer

    Article • Hematology/Oncology Clinics of North America, December 2018, Elsevier

    Dr Elizabeth L Christie

  31. Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma

    Article • Stem Cells, November 2018, Wiley

    Dr Elizabeth L Christie

  32. Neutral tumor evolution?

    Article • Nature Genetics, October 2018, Springer Science + Business Media

    Dr Elizabeth L Christie

  33. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

    Article • BMC Cancer, January 2018, Springer Science + Business Media

    Dr Elizabeth L Christie

  34. Acquired chemotherapy resistance in ovarian cancer

    Article • Annals of Oncology, November 2017, Oxford University Press (OUP)

    Dr Elizabeth L Christie

  35. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

    Article • Clinical Cancer Research, October 2017, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  36. EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas

    Article • Cancer Research, June 2017, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  37. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer

    Article • Journal of Clinical Oncology, April 2017, American Society of Clinical Oncology (ASCO)

    Dr Elizabeth L Christie

  38. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

    Article • November 2016, Cold Spring Harbor Laboratory Press

    Dr Elizabeth L Christie

  39. Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker

    Article • Cancer Research, October 2016, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  40. A community-based model of rapid autopsy in end-stage cancer patients

    Article • Nature Biotechnology, September 2016, Nature

    Dr Elizabeth L Christie

  41. Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer

    Article • Nature, October 2015, Nature

    Dr Elizabeth L Christie

  42. Whole–genome characterization of chemoresistant ovarian cancer

    Article • Nature, May 2015, Nature

    Dr Elizabeth L Christie

  43. LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

    Article • Cancer Research, August 2012, American Association for Cancer Research (AACR)

    Dr Elizabeth L Christie

  44. Abnormal Nuclear Pore Formation Triggers Apoptosis in the Intestinal Epithelium of elys-Deficient Zebrafish

    Article • Gastroenterology, March 2009, Elsevier

    Dr Elizabeth L Christie

  45. Determination of mRNA and Protein Expression Patterns in Zebrafish

    Article • January 2008, Springer Science + Business Media

    Dr Elizabeth L Christie